This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Inclusion Criteria:

• Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation.
• Health Care Provider (HCP) must have prior clinical trial experience with ABT-414.
• The participant must not be eligible for an ABT-414 clinical trial.
• Pediatric participants may be evaluated on a case by case basis.